As per the agreement, Teva subsidiary Salomon, Levin, Elstein will not only distribute Canndoc’s products in Israel, but also seek to “provide logistics capability for exporting Canndoc’s products to countries that support regulations for the sale and distribution of cannabis products for medical use,” as soon as local regulations allow for it, Canndoc, a subsidiary of publicly traded company InterCure, explained.
The initial agreement will span for three years, but a term to automatically extend it for two-year periods at a time is included in the deal.While this is not the first deal between a big pharma company and a cannabis-related business, it is among the couple notable ones to date – pharma is being careful with its approach to marijuana, hemp, CBD and related industries.The other big deal announced to date: a development and distribution deal between Novartis and Tilray.
Johnson & Johnson has also been getting its feet wet in the proverbial canna-pond. Back in 2017, the company’s incubator, JLABS @ Toronto,Beyond specific deals, a few big pharma companies have
Well this is absolutely terrible news. Pot should stay small & local. Keep corporate fingers out of the honeypot
The oligarchy can benefit? Well, time to make it legal and shut out the small entrepreneurs while giving unfair tax breaks to the evil giant corporations then...
It really does work for glaucoma. I watched it happen for an elderly friend of mine. He used to have to get shots in his eyeball. He took PRANA and he no longer had to get shots in his eyes from Kaiser.
Sverige Senaste nytt, Sverige Rubriker
Similar News:Du kan också läsa nyheter som liknar den här som vi har samlat in från andra nyhetskällor.
Källa: Forbes - 🏆 394. / 53 Läs mer »
Källa: Forbes - 🏆 394. / 53 Läs mer »
Källa: MarketWatch - 🏆 3. / 97 Läs mer »